SCHEDULE: Vanguard Group Amends Gossamer Bio Stake to Zero

The Vanguard Group has filed an Amendment No. 6 to Schedule 13G, reporting zero beneficial ownership in Gossamer Bio Inc. Common Stock following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 6 to Schedule 13G regarding its beneficial ownership in Gossamer Bio Inc. Common Stock.
• The filing indicates that The Vanguard Group now holds 0% of Gossamer Bio Inc.'s Common Stock, with 0 shares beneficially owned.
• This change is attributed to an internal realignment within The Vanguard Group, Inc., effective January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update from The Vanguard Group regarding its internal reporting structure, with no direct positive or negative implications for Gossamer Bio Inc's operational performance or valuation.

Future Outlook

NA

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects an internal administrative change within The Vanguard Group's reporting structure, rather than a strategic divestment from Gossamer Bio Inc. This type of realignment is common among large asset managers to comply with regulatory interpretations, and does not necessarily indicate a change in investment thesis for the underlying company.

Stakeholder Impact

• Shareholders of Gossamer Bio Inc: May initially perceive a large institutional investor divesting, but the explanation clarifies it's a reporting change, not a true divestment. The underlying shares are likely still held by Vanguard's subsidiaries.
• The Vanguard Group: This change impacts their internal reporting and compliance procedures.

Key Dates

Keywords

Gossamer Bio Inc, Vanguard Group, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional ownership, investment adviser, realignment